Premium
Private equity giant KKR is considering a new multi-billion dollar plan to monetise its four-year-old bet on JB Chemicals & Pharmaceuticals Ltd, also known as JB Pharma, after preliminary talks with several suitors to sell its stake in the drugmaker stalled over differences on valuation. KKR has been in talks with ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
